Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Access Pharmaceuticals, Inc.; MacroChem Corporation
Access Pharmaceuticals Signs Merger Agreement to Acquire MacroChem Corp.
July 25th, 2008
Access Pharmaceuticals, Inc. (BULLETIN BOARD: ACCP) and MacroChem Corporation (BULLETIN BOARD: MACM) announced that they had signed a definitive merger agreement providing for Access to acquire MacroChem through the issuance of 2.5 million shares of Access Pharmaceuticals' common stock. MacroChem's product portfolio includes two clinical stage oncology products, 4-thio Ara-C, which is a next generation nucleoside analogue licensed from Southern Research Institute and sodium phenylbutyrate, which is licensed from the NIH and is currently partnered with Access Pharmaceuticals. MacroChem's portfolio of late stage clinical drug candidates includes Pexiganan, a novel topical anti-infective for...
Source: Health Business Week (2008-07-25)
|
